X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5081) 5081
Publication (662) 662
Book Review (68) 68
Book Chapter (12) 12
Conference Proceeding (9) 9
Dissertation (5) 5
Magazine Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nivolumab (4458) 4458
oncology (2735) 2735
index medicus (2521) 2521
immunotherapy (2309) 2309
humans (2062) 2062
ipilimumab (1554) 1554
pembrolizumab (1510) 1510
cancer (1443) 1443
melanoma (1426) 1426
chemotherapy (1118) 1118
docetaxel (1048) 1048
male (928) 928
open-label (891) 891
female (864) 864
metastasis (817) 817
lung cancer (774) 774
care and treatment (767) 767
middle aged (757) 757
aged (741) 741
pd-1 (704) 704
patients (694) 694
survival (685) 685
immunology (683) 683
tumors (674) 674
safety (665) 665
therapy (571) 571
pd-l1 (541) 541
cancer therapies (539) 539
blockade (538) 538
antibodies, monoclonal - therapeutic use (536) 536
metastatic melanoma (511) 511
immune checkpoint (483) 483
adult (481) 481
cell lung-cancer (471) 471
programmed cell death 1 receptor - antagonists & inhibitors (459) 459
apoptosis (458) 458
clinical trials (452) 452
multicenter (447) 447
antineoplastic agents - therapeutic use (446) 446
analysis (439) 439
expression (437) 437
treatment outcome (430) 430
research (426) 426
pd-1 blockade (410) 410
lymphocytes (404) 404
lung cancer, non-small cell (396) 396
advanced melanoma (393) 393
prognosis (387) 387
lung neoplasms - drug therapy (379) 379
immunotherapy - methods (372) 372
melanoma - drug therapy (371) 371
respiratory system (365) 365
aged, 80 and over (355) 355
biomarkers (355) 355
drug therapy (349) 349
neoplasms. tumors. oncology. including cancer and carcinogens (348) 348
antibodies, monoclonal - adverse effects (338) 338
non-small cell lung cancer (334) 334
immune checkpoint inhibitors (332) 332
mutation (321) 321
pd-1 protein (317) 317
adverse events (311) 311
medicine & public health (309) 309
medical research (306) 306
metastases (297) 297
antineoplastic agents, immunological - therapeutic use (288) 288
medicine, research & experimental (286) 286
cell death (284) 284
carcinoma, non-small-cell lung - drug therapy (283) 283
antibody (281) 281
untreated melanoma (279) 279
medical prognosis (278) 278
t-cells (278) 278
ligands (276) 276
health aspects (275) 275
pharmacology & pharmacy (271) 271
immunohistochemistry (268) 268
anti-pd-1 (267) 267
pd-l1 protein (266) 266
lung neoplasms - pathology (265) 265
programmed cell death 1 receptor - immunology (264) 264
usage (262) 262
atezolizumab (261) 261
t cells (257) 257
checkpoint inhibitors (250) 250
case report (246) 246
article (242) 242
trial (239) 239
antineoplastic agents - adverse effects (238) 238
review (237) 237
development and progression (236) 236
antibodies (235) 235
carcinoma (235) 235
immune checkpoint inhibitor (231) 231
dermatology (229) 229
cytotoxicity (228) 228
combined nivolumab (227) 227
melanoma - pathology (227) 227
animals (224) 224
antineoplastic agents, immunological - adverse effects (218) 218
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4862) 4862
French (78) 78
German (62) 62
Japanese (23) 23
Russian (19) 19
Korean (13) 13
Spanish (10) 10
Chinese (6) 6
Czech (5) 5
Italian (4) 4
Polish (3) 3
Danish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 06/2018
Journal Article
Ophthalmology, ISSN 0161-6420, 07/2019, Volume 126, Issue 7, pp. 1058 - 1062
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2018, Volume 29, Issue 4, pp. 1065 - 1066
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 17, pp. 1668 - 1674
Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited... 
CRITERIA | ONCOLOGY | NIVOLUMAB | IPILIMUMAB
Journal Article
The Oncologist, ISSN 1083-7159, 12/2018, Volume 23, Issue 12, pp. e159 - e161
Central nervous system metastasis in non‐small cell lung cancer remains a therapeutic challenge and confers a poor prognosis. Here we describe a patient with... 
ONCOLOGY | NIVOLUMAB
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 17, pp. 1658 - 1667
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II... 
ONCOLOGY | NIVOLUMAB | PEMBROLIZUMAB | Rapid Communications
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2017, Volume 28, Issue 12, pp. 3104 - 3106
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 03/2016, Volume 14, Issue 3, pp. 255 - 264
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines... 
PEMBROLIZUMAB | ONCOLOGY | NIVOLUMAB | IMMUNOTHERAPY | SAFETY | DOCETAXEL
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2019, Volume 37, Issue 12, pp. 1031 - 1031
Journal Article
Cancer Cell, ISSN 1535-6108, 05/2018, Volume 33, Issue 5, pp. 853 - 861.e4
Journal Article
Annals of Oncology, ISSN 0923-7534, 07/2016, Volume 27, Issue 7, pp. 1356 - 1360
Case series of four platinum refractory germ cell tumor patients treated with anti-PD-1 antibodies showing efficacy in one patient with a PD-L1 positive tumor. 
ONCOLOGY | PD-L1 | NIVOLUMAB
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 2, pp. 434 - 435
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2019, Volume 14, Issue 1, pp. e5 - e7
Journal Article
Acta Oncologica, ISSN 0284-186X, 07/2019, Volume 58, Issue 7, pp. 962 - 966
Introduction: Phase III studies of PD-1 inhibitors have demonstrated remarkable improvements in the survival of patients with metastatic melanoma (MM). If... 
BRAF | ONCOLOGY | NIVOLUMAB | IPILIMUMAB
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2019, Volume 25, Issue 3, pp. 989 - 999
Purpose: Hyperprogression (HP), a paradoxical boost in tumor growth, was described in a subset of patients treated with immune checkpoint inhibitors (ICI).... 
MICROENVIRONMENT | ONCOLOGY | NIVOLUMAB | PD-L1 EXPRESSION | ADENOCARCINOMA
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 01/2017, Volume 44, Issue 1, pp. 59 - 62
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 09/2015, Volume 38, Issue 9, pp. 473 - 473
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.